EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations

The American Medical Association (AMA) is expected to issue the first code for psychedelic therapy reimbursement, following the approval of a joint application submitted by MAPS PBC and COMPASS Pathways (NASDAQ: CMPS).

On March 3, the AMA published its Panel Actions summary which included the approval of the new Current Procedural Terminology (CPT) III code.

These types of codes are temporary and allotted to emerging technologies, services and procedures aimed at data collection to substantiate more widespread usage or to provide documentation for Food and Drug Administration (FDA) approval process. Read more HERE.

Amanita Muscaria Mushrooms Are Taking The Lead In Markets As Research Ramps Up

Amanita Muscaria is the only kind of mushroom currently legal. As its health benefits are regularly being confirmed in studies, demand for related products is rapidly growing.

This scenario has compelled Colorado-based Panacea Life Sciences (OTCMKTS: PLSH) to conduct research and formulation design for product development expansion. 

Amanita Muscaria contains ibotenic acid, muscarine, muscazone and muscimol. Their pharmacology is “psychoactive” in the sense that it produces sedative and hallucinogenic effects as well as nausea, which is why it has been used for analgesic, anti-inflammatory and anxiolytic purposes at different doses, as well …

Full story available on Benzinga.com

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.